drugset / Trial / NCT00091793

Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

NCT00091793

Phase 3 Completed 332 enrolled Amgen
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.

Timeline

Start
2004-08
Primary completion
2009-02
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous